Microbot Medical says Emory University Hospital in Atlanta is the first worldwide to embrace its Liberty endovascular robotic ...

Microbot Medical Inc. has announced the addition of two senior executives to enhance its U.S. commercial leadership team in preparation for the upcoming launch of its LIBERTY® Endovascular Robotic ...

Roth Capital analyst Kyle Bauser initiated coverage of Microbot Medical (MBOT) with a Buy rating and $5.50 price target The firm says the ...

Microbot Medical Inc. announces key milestones, including FDA 510(k) submission, in preparation for LIBERTY's commercial launch in 2025. Microbot Medical Inc. announced the successful completion of ...

HINGHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributer of the innovative LIBERTY ® Endovascular Robotic System, today announced that it will ...

BRAINTREE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Endovascular Robotic Surgical System, today announced that it has ...

Liberty is a remotely operated robotic system for peripheral endovascular procedures and has received FDA clearance.

Investing.com -- Microbot Medical Inc. (NASDAQ:MBOT) stock rose 5.8% Wednesday after the company announced the commercial availability of its LIBERTY® Endovascular Robotic System in the United States.